An interventional study of Cardiac rehabilitation and Usual care in Heart Failure Congenital and Single-ventricle, sponsored by Stanford University. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-05.
Sponsored by Stanford University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Univentricular Heart with a site in United States — 13 open to participants now, 16 under way, none of them phase 3. Univentricular Heart · United States.
Among the 55 studies in Univentricular Heart with a site in United States, this one is the 9th largest by planned enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2024, is one of 17 with no phase, reaches primary completion later than 4 of the 15 other live ones, and was the 45th registered.
86 studies on the registry are indexed under Univentricular Heart; 22 are open to participants now.
Browse Univentricular Heart studies →13 of the 55 studies in Univentricular Heart with a site in United States are open now. Recruiting first, the newest first:
Le Bonheur Children's Hospital · Sites in United States
Ages 0 mo–12 mo
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–45 · Healthy volunteers
Children's Hospital Los Angeles · Sites in United States
Ages 12–21
Driscoll Children's Hospital · Sites in United States
Ages 0 mo–6 mo
Children's Hospital of Philadelphia · Sites in United States
Ages 10–17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 21 Univentricular Heart studies recruiting now, 8 (38%) set no upper age limit and 13 (62%) stop at 75 or younger; 16 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 4 · Phase 4 2
First in 2000; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is above the median of 28 across 44 interventional studies indexed under Univentricular Heart.
Median enrollment 24 across the 32 interventional studies, 30 across the 23 observational. Of the 36 that completed or were terminated, 12 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 55 have an industry lead sponsor. The 10 most frequent:
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
Stanford University has 3 studies filed under Univentricular Heart — fewer than ten, so there is no comparison to draw.
5 of the studies in Univentricular Heart with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06434207Boston Children's HospitalExtracellular Vesicle Micro RNA Profiling in Congenital Heart Disease: Fetal-Maternal Regulation in Neonatal Thrombosis | 2026-12-01 |
| NCT06150950Stanford UniversityREHAB Fontan Failure: A Trial of Cardiac Rehabilitation | 2026-12-31 |
| NCT05262907Duke UniversityVentripoint Single Ventricle Study | 2027-08 |
| NCT05647213HeartWorks, Inc.Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease | 2027-09 |
| NCT07220226University of Texas Southwestern Medical CenterVenous Compression in Fontan | 2027-11-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 55 studies in Univentricular Heart with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to compare the impact of cardiac rehabilitation on Fontan failure patients' exertional tolerance, frailty, and quality of life.
REHAB Fontan Failure is a a multi-center, non-blinded, randomized clinical trial evaluating the effect of cardiac rehabilitation compared to usual care on exercise tolerance among adults with Fontan failure. Eligible study subjects will be identified from clinical chart review and study informational fliers will be sent to Adult Congenital Heart Disease (ACHD) cardiologists at all centers. Fontan failure patients being evaluated for outpatient care at ACHD centers and meeting eligibility criteria will be enrolled and randomly assigned to either cardiac rehabilitation or usual clinical care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For patient randomized to cardiac rehabilitation, the ACHD clinician will place the referral after they and the patient have seen the group assignment. All participants will be referred to Heart Fit for Life community-based cardiac rehabilitation program in Palo Alto, CA. Cardiac rehabilitation will be offered as an in-person, hybrid, or completely virtual program for Stanford participants and will be entirely virtual for Vanderbilt participants. Participants will attend 3 sessions per week for 12 weeks. Participants will receive weekly email reminders via the electronic medical record to encourage participation. The study protocol pertains only to referral to cardiac rehabilitation. All other aspects of the cardiac care will be at the discretion of clinicians. All study participants will receive a Fitbit for daily activity tracking.
Behavioral: Cardiac rehabilitation
For patients randomized to the usual care (no cardiac rehabilitation group), cardiac rehabilitation will not be initiated between randomization and for up to 16 weeks following randomization. The study protocol controls only referral to cardiac rehabilitation. All other aspects of the cardiac care, such as titration of guideline directed medical therapy will be at the discretion of clinicians. All study participants will receive a Fitbit for daily activity tracking.
Other: Usual care
Cardiac rehabilitation is a multifaceted, comprehensive therapeutic intervention of personalized, supervised exercise training that is beneficial and well-studied among patients with non-ACHD heart failure and has consistently been shown to improve QOL. Unfortunately, cardiac rehabilitation has been underutilized with an overall participation \<50% of eligible patients despite international guidelines advocating for more consistent deployment of cardiac rehabilitation. A major a barrier to cardiac rehabilitation is access, as CMS-mandates a physician be within 3 minutes of the rehabilitation facility to assure insurance reimbursement. This mandate limits isolated, outpatient cardiac rehabilitation programs, especially in rural communities.
For participants randomized to the usual care (no cardiac rehabilitation group), cardiac rehabilitation will not be initiated between randomization and for up to 16 weeks following randomization. The study protocol controls only referral to cardiac rehabilitation. All other aspects of the cardiac care, such as titration of guideline directed medical therapy will be at the discretion of clinicians.
Average daily step count
Average daily step count during the intervention period measured by Fitbit 3 activity tracker
Time frame: 120 days (+/- 45 days) post-randomization
Change in 5-meter timed walk as a measure of slowness
Time frame: Baseline and 120 days (+/- 45 days) post-randomization
Change in exercise time as a measure of exhaustion
Exercise time on cardiopulmonary exercise testing
Time frame: Baseline and 120 days (+/- 45 days) post-randomization
Change in respiratory exchange ratio (RER) as a measure of exhaustion
RER on cardiopulmonary exercise testing (exhaustion)
Time frame: Baseline and 120 days (+/- 45 days) post-randomization
Change in mini-nutritional assessment short form (MNA-SF) score
Nutrition score as measured by MNA-SF; range 0-14; malnourished 0-7, 8-11 at-risk, and 12-14 normal nutritional status
Time frame: Baseline and 120 days (+/- 45 days) post-randomization
Change in body fat percentage
Body fat percentage is a measure of body composition
Time frame: Baseline and 120 days (+/- 45 days) post-randomization
Change in grip strength
Time frame: Baseline and 120 days (+/- 45 days) post-randomization
Change in patient reported physical activity questionnaire score
The physical activity questionnaire score ranges from 0 - 10,000 kilo-calories/week, with higher scores representing higher physical activity.
Time frame: Baseline and 120 days (+/- 45 days) post-randomization
Change in Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) scale score
KCCQ-12 is a 12 question questionnaire, participants completed questionnaire about how heart failure affected their life over the past 2 weeks. The scale has 4 domains: symptom frequency, physical limitation, social limitations and quality of life for a total possible transformed score of 0 to 100 where 100 denotes the highest health status. A positive change from baseline indicates improvement.
Time frame: Baseline and 120 days (+/- 45 days) post-randomization
Change Patient Health Questionnaire-2 (PHQ-2) score
Mood assessment (Range 0-6, higher score indicates higher risk of depression, \>=3 suggestive of depression)
Time frame: Baseline and 120 days (+/- 45 days) post-randomization
Average daily active minutes
Total average daily active minutes from Fitbit
Time frame: Baseline and 120 days (+/- 45 days) post-randomization
Average daily active minutes of moderate-high intensity activity
Average daily active minutes of moderate-high intensity activity from Fitbit
Time frame: Baseline and 120 days (+/- 45 days) post-randomization
Average daily sedentary minutes
Average daily sedentary minutes from Fitbit
Time frame: Baseline and 120 days (+/- 45 days) post-randomization
Change in peak respiratory oxygen uptake (VO2)
Peak VO2 on follow-up cardiopulmonary exercise testing, adjusted for baseline
Time frame: Baseline and 120 days (+/- 45 days) post-randomization
Change in oxygen (O2) pulse
O2 pulse on follow-up cardiopulmonary exercise testing, adjusted for baseline
Time frame: Baseline and 120 days (+/- 45 days) post-randomization
Change in minute ventilation/carbon dioxide production (VE/VCO2)
VE/VCO2 on follow-up cardiopulmonary exercise testing, adjusted for baseline
Time frame: Baseline and 120 days (+/- 45 days) post-randomization
Change in anaerobic threshold
Anaerobic threshold on follow-up cardiopulmonary exercise testing, adjusted for baseline
Time frame: Baseline and 120 days (+/- 45 days) post-randomization
Exploratory outcome: number of participants with exercise-induced clinical ailment
Sustained arrhythmia or hemodynamic change necessitating hospitalization, heart failure hospitalization, or all-cause death within 30 days of completion of cardiac rehabilitation
Time frame: 120 days (+/- 45 days) post-randomization
Plan to share: No
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.
Of 20 interventional studies with no phase under Univentricular Heart, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 63. This study's planned 31 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.